AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$TNON

HRT FINANCIAL LP sold $2K of TNON

HRT FINANCIAL LP sold 419 shares of Tenon Medical, Inc. (TNON) at $4.96 on 2026-08-27.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Aug 31, 2026, 7:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 7:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TNON
Neutral
high confidence
Mentioned
$TNON
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNONNeutralLow
01

Why it matters

The sale is routine and does not provide new material insight into the company's fundamentals.

02

Market read

Limited relevance; typical micro‑cap insider sell with negligible market impact.

03

What to watch

Potential upcoming clinical data or regulatory news could change relevance.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-31

Background

Tenon Medical is a small-cap medical device company; insider transactions are regularly disclosed via Form 4.

Company-level read

Ticker impact

$TNONNeutralHigh confidence
Context

Form 4 shows HRT FINANCIAL LP sold 419 shares of Tenon Medical at $4.96, reducing its stake to 9,604 shares.

Expected impact

No significant impact; possible slight downward pressure.

Evidence & confidence

The transaction size (~$2k) is trivial for the market and does not indicate material information.

Market effects

Sector

None; Tenon Medical operates in a niche medical device segment.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings for pattern.

Key entities

  • company
    Tenon Medical, Inc.

    Issuer of the securities sold.

  • insider
    HRT FINANCIAL LP

    Seller and 10% owner.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNON insider trading history →

Related articles

SEP 11
$TNONHigh

Tenon Medical TNON Jumps As Debt Risk Fades

Tenon Medical Inc. (NASDAQ: TNON) shares surged 53.64% after repaying $5.16M in convertible notes, reducing debt risk. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin. Despite strong growth, TNON faces financial challenges, including a $4.05M net loss and negative equity. Traders are monitoring the stock due to its volatility and recent catalysts, such as FDA clearance and increased surgical volume.

timothysykes.com3 min
SEP 11
$TNONHigh

Tenon Medical TNON Jumps After Early Debt Repayment

Tenon Medical Inc. (TNON) shares rose 55.66% after repaying $5.16M in convertible notes early. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin, but a net loss of $4.05M. TNON's stock is highly volatile, driven by news and liquidity rather than fundamentals.

stockstotrade.com2 min
SEP 11
$TNONHigh

Tenon Medical TNON Stock Jumps As Debt Overhang Vanishes

Tenon Medical Inc. (TNON) stock surged 56.04% on September 11, 2026, following the company's repayment of $5.16M in convertible notes, removing a dilution risk. Q2 revenue grew 127% YoY to $1.3M, with a 64% gross margin, but the company remains unprofitable. TNON regained Nasdaq compliance and reported record surgical case volume.

stockstotrade.com3 min
SEP 11
$TNONHigh

Tenon Medical TNON Jumps As Debt Overhang Clears

Tenon Medical Inc. (TNON) shares rose 55.66% after the company cleared $5.16M in debt ahead of schedule, improving its balance sheet. The stock has shown high volatility, with a recent surge from $2.44 to $5.30. TNON reported Q2 2026 revenue growth of 127% YoY to $1.3M, but remains unprofitable with a net loss of $4.1M. The company secured FDA clearance for a medical device and regained Nasdaq compliance, but faces liquidity challenges and potential future capital raises.

timothysykes.com2 min